Login to Your Account

Takara Bio expands gene therapy pipeline

By Cornelia Zou
Staff Writer

Wednesday, February 19, 2014

HONG KONG – With a supportive environment for regenerative medicine created by the Japanese government, Takara Bio Inc. (TYO: 4974), has launched a phase I clinical trial to study its MAGE-A4 antigen-specific T-cell receptor (TCR) gene therapy in esophageal cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription